Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.

Michael Brands1, Jens-Kerim Ergüden, Kentaro Hashimoto

  • 1Bayer HealthCare AG, Business Group Pharma, Research & Development, Aprather Weg 18a, 42096 Wuppertal, Germany.

Chemmedchem
|August 8, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8<sup>+</sup> T cell responses and promoting tertiary lymphoid structure formation.

Nature communications·2026
Same author

Specific ion effects on long-range correlations of amino acids in aqueous solution from experimental and computational dielectric spectra.

The Journal of chemical physics·2026
Same author

Parametrizing reaction probabilities for proton transfers in protic ionic liquids.

Frontiers in chemistry·2026
Same author

Clinical Validation of Plasma p-217tau in Neurological Diseases.

Annals of clinical and translational neurology·2026
Same author

Biliary obstruction post-liver transplantation: cast a wide net.

iGIE : innovation, investigation and insights·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes.

British journal of pharmacology·2025

Novel indole-based inhibitors targeting endothelin-converting enzyme-1 (ECE-1) show promise for treating cardiovascular diseases. These compounds effectively lower blood pressure and offer cardio-protection, with high selectivity for ECE-1.

Area of Science:

  • Medicinal Chemistry
  • Cardiovascular Pharmacology
  • Enzyme Inhibition

Background:

  • Endothelin-1 (ET-1) plays a crucial role in cardiovascular diseases.
  • Endothelin-converting enzyme-1 (ECE-1) is a key metalloprotease in the ET-1 pathway.
  • Inhibiting ECE-1 presents a therapeutic strategy for conditions like coronary heart disease, cancer, and renal failure.

Purpose of the Study:

  • To identify and optimize novel indole-based inhibitors of ECE-1.
  • To evaluate the therapeutic potential of these inhibitors in preclinical models of cardiovascular disease.

Main Methods:

  • High-throughput screening to identify initial lead compounds.
  • Structure-activity relationship studies for lead optimization.
  • In vivo testing in rat and mouse models for antihypertensive and cardio-protective effects.

Related Experiment Videos

  • Molecular docking to elucidate binding modes.
  • Enzyme selectivity assays against related metalloproteases (NEP, ACE).

    • Main Results:

    • A novel class of indole-based ECE-1 inhibitors was discovered.
    • Optimized compounds, such as derivative 11, exhibit potent inhibition.
    • Lead compound 6 demonstrated antihypertensive effects and cardio-protection in vivo.
    • Chloropyridine derivative 9 effectively antagonized ET-1-induced hypertension.
    • Indole-class inhibitors showed high selectivity for ECE-1 over NEP and ACE.

    Conclusions:

    • Novel indole-based ECE-1 inhibitors possess significant therapeutic potential.
    • These compounds demonstrate efficacy in preclinical models relevant to cardiovascular diseases.
    • The observed selectivity suggests a favorable safety profile for further drug development.